



## Wednesday 25 September 2019

### SESSION 1: HDL Structure, function and subspéciation

CHAIRS: John Chapman & Daisy Sahoo

14.00 - 14.20	HDL protein- based speciation: connecting epidemiology and metabolism	Frank Sacks USA
14.20 - 14.40	High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes	Amy Shah USA
14.40 - 15.00	Free cholesterol transfer to HDL from triglyceride-rich lipoproteins upon their lipolysis by lipoprotein lipase, HDL-cholesterol and cardiovascular disease	Anatol Kontush France

### SESSION 2: Regulation of HDL Function and Metabolism

CHAIRS: Len Kritharides & Miranda van Eck

15.00 - 15.20	HDL and atherosclerosis. Insights from inherited HDL disorders	Laura Calabresi Italy
15.20 - 15.40	Small RNA cargo and novel functions contribute to the inflammatory potential of HDL	Kasey C. Vickers USA
15.40 - 15.55	Targeting cholesterol efflux to inflammatory cells	Yury Miller USA
15.55 - 16.10	Sexually dimorphic regulation of HDL and atherosclerosis by miRNAs	Elizabeth Tarling USA

### 16.10 - 16.40 AFTERNOON TEA BREAK

16.40 - 17.10 **Panel Discussion:** The future of HDL as a therapeutic target  
*Phil Barter, Ruth Frikke-Schmidt, Shinji Yokoyama, Marina Cuchel*

Chair: Frank Sacks

### SESSION 3: Oral finalists - ECR and student

CHAIR: Monica Gomaschi

JUDGES: Miranda Van Eck, Bronwyn Kingwell, Yury Miller

17.10 - 17.25	High Density Lipoprotein as a Modulator of Protease Activity in Atherosclerosis	Scott Gordon USA
17.25 - 17.40	Cerebrovascular Amyloid Angiopathy in Bioengineered Vessels is Reduced by High-Density Lipoprotein Particles Enriched in Apolipoprotein E	Cheryl Wellington Canada
17.40 - 17.55	Genetic LCAT deficiency: role of the accumulation of pre- $\beta$ HDL in the pathogenesis of renal disease	Ariana Strazzella Italy
17.55 - 18.10	Neonatal HDL (nHDL)- sphingosine-1-phosphate (S1P) complex preserves the integrity of the feto-placental endothelium	Ilaria Del Gaudio Austria

## Thursday 26 September 2019

### SESSION 4: HDL and Infection

CHAIRS: Maaike Kockx & Tomas Vaisar

8.30 - 8.50	HDL in sepsis – A risk factor and therapeutic approach	Anna Schwendeman USA
8.50 - 9.10	Genetic regulation of HDL levels during sepsis	Liam Brunham Canada
9.10 - 9.25	Prevention of fatal hepatic complication in schistosomiasis by inhibiting the HDL receptor pathway of the parasites.	Shinji Yokoyama Japan
9.25 - 9.40	Reconstituted High-Density Lipoprotein therapy improves survival in mouse models of sepsis	Olivier Meilhac France

### SESSION 5: Poster finalists (mini-oral) - ECR and student

CHAIR: Anna Schwendeman

JUDGES: Anna Schwendeman, Liam Brunham, Kasey Vickers, Anatol Kontush

9.40 - 9.50	Synthetic HDL nanoparticles for the treatment of Niemann-Pick disease type C	Maria Fawaz USA
9.50 - 10.00	Paraoxonase 1 endocytosis and activity in endothelial cells	Raz Ben-David Israel
10.00 - 10.10	HDL proteins enhance survival of human regulatory T lymphocytes by regulating caspase-dependent apoptosis and redox balance	Laura Atehortua USA
10.10 - 10.20	Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion	Oktawia Nilsson Sweden

10.20 - 10.55	MORNING TEA BREAK	
<b>SESSION 6: Gerontology of HDL</b> <span style="float: right;"><b>CHAIRS: Robert Rosenson &amp; Cheryl Wellington</b></span>		
10.55 – 11.15	HDL cholesterol in dementia and other age-related diseases	Ruth Frikke-Schmidt <b>Denmark</b>
11.15 – 11.35	HDL subspeciation, brain structure and dementia risk	Majken Jensen <b>USA</b>
11.35 – 11.50	ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is specifically impaired in Alzheimer's disease	Francesca Zimetti <b>Italy</b>
11.50 – 12.05	HDL inhibit the proliferation of prostate cancer cells by reducing cell oxidative stress and cholesterol content	Monica Gomaschi <b>Italy</b>
12.05 – 13.00	LUNCH	
13.00 – 14.00	DEDICATED POSTER SESSION - All authors to stand beside posters for Q&A	
<b>SESSION 7: Atheroma Development and Immunity</b> <span style="float: right;"><b>CHAIRS: Jayne Raper &amp; Shinji Yokoyama</b></span>		
14.00 – 14.20	Cholesterol efflux pathways suppress inflammasome activation and NETosis in atherosclerotic plaques	Marit Westerterp <b>The Netherlands</b>
14.20 – 14.40	Assessing reverse cholesterol transport in humans.	Marina Cuchel <b>USA</b>
14.40 – 15.00	Immunity, Scavenger Receptors and Atherosclerosis	Mary Sorci-Thomas <b>USA</b>
15.00 – 15.30	<b>Panel Discussion - Is HDL function the key?</b> <i>Arnold Von Eckardstein, Jacques Genest, Sean Davison, Kerry-Anne Rye</i>	<b>Chair: Laura Calabresi</b>
15.30 – 16.00	AFTERNOON TEA BREAK	
<b>SESSION 8: Cardiometabolic functions of HDL</b> <span style="float: right;"><b>CHAIRS: Jacques Genest &amp; Bronwyn Kingwell</b></span>		
16.00 – 16.20	Mechanistic insights into the anti-diabetic functions of HDL	Kerry-Anne Rye <b>Australia</b>
16.20 – 16.40	A systems biology approach identifies novel mediators of HDL's vasoprotective and anti-diabetic functions	Arnold von Eckardstein <b>Switzerland</b>
16.40 – 16.55	Tissue-specific amyloid deposition of rare ApoA-I variants is driven by distinctive interactions with different extracellular milieus	Rita Del Giudice <b>Sweden</b>
16.55 – 17.10	The HDL proteome as a novel indicator of metabolic health in obesity - the metabolic HDL index score (MHI)	Fiona McGillicuddy <b>Ireland</b>
19.00 – 22.00	<b>CONFERENCE AWARDS DINNER</b>	
<b>Friday 27 September 2019</b>		
<b>SESSION 9: HDL from Bench to Bedside</b> <span style="float: right;"><b>CHAIRS: Eliot Brinton &amp; Marina Cuchel</b></span>		
9.00 – 9.35	<b>Keynote Lecture</b> Lecithin: Cholesterol Acyltransferase: Bench to Bedside	Alan Remaley <b>USA</b>
9.35 – 9.50	Cholesterol efflux capacity in patients with schizophrenia	Maaïke Kockx <b>Australia</b>
9.50 – 10.05	HDL cholesterol efflux capacity is associated with prolonged QTc in people at high risk for CVD events.	Tomas Vaisar <b>USA</b>
10.05 – 10.20	Allergic rhinitis is associated with complex alterations in HDL composition, metabolism and function	Gunther Marsche <b>Austria</b>
10.20 - 10.50	MORNING TEA BREAK	
<b>SESSION 10: Update on HDL-based therapies</b> <span style="float: right;"><b>CHAIRS: Franco Bernini &amp; Anand Rohatgi</b></span>		
10.50 - 11.10	Development of infused apoA-I as a therapeutic agent: Current status	Sam Wright <b>USA</b>
11.10 - 11.25	ApoA-I Nanoparticles (CSL-111) Directly Modulate Inflammatory Cells after Myocardial Infarction in Mice	Bronwyn Kingwell <b>Australia</b>
11.25 – 11.40	Chemical compounds targeting desmocollin 1: a new paradigm for HDL-directed therapies	Jacques Genest <b>Canada</b>
11.40 – 12.00	HDL-targeted gene transfer and reconstituted HDL for treatment of heart failure	Bart De Geest <b>Belgium</b>
12.00 – 12.15	Closing comments	Kerry-Anne Rye <b>Australia</b>